Nine Chapters Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Nine Chapters Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-43,400	Closed	-$1.03M	–	1305
2014 Q3	$1.03M	Buy	43,400 +11,000	+34%	+$282K	0.09%	302
2014 Q2	$972K	Sell	32,400 -50,000	-61%	-$1.35M	0.08%	346
2014 Q1	$2.18M	Buy	82,400 +28,400	+53%	+$710K	0.26%	92
2013 Q4	$1.36M	Buy	+54,000	New	+$1.2M	0.14%	225

Other funds holding IPXL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Nine Chapters Capital Management's IPXL Position: Q4 2014 in Review

Nine Chapters Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q4 2014, closing a stake of 43,400 shares — an estimated $1.03M sold.

Nine Chapters Capital Management first reported a position in IPXL in Q4 2013 and held it in 4 quarters. The position peaked at $2.18M in Q1 2014. 178 funds tracked by Wall St. Rank hold IPXL as of Q4 2014.

Nine Chapters Capital Management reported no remaining Impax Laboratories, Inc. position as of Q4 2014 after selling out during the quarter.
Nine Chapters Capital Management sold 43,400 Impax Laboratories, Inc. shares in Q4 2014, an estimated $1.03M.
Nine Chapters Capital Management first reported a position in Impax Laboratories, Inc. in Q4 2013 and held it in 4 quarters.
Nine Chapters Capital Management's Impax Laboratories, Inc. position peaked at $2.18M in Q1 2014.
178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2014.

Based on Nine Chapters Capital Management's 13F filing for Q4 2014, filed 9 Feb 2015.